Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2010-06-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2010.04.129PMID 20493689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.

  2010cited by this paper
• Potent inhibitors of HCV-NS3 protease derived from boronic acids.

  2009cited by this paper
• Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.

  2009cited by this paper
• Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

  2009cited by this paper
• Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

  2008cited by this paper
• Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.

  2008cited by this paper
• Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

  2008cited by this paper
• An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site

  2007cited by this paper
• Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

  2006cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006cited by this paper
• Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

  2006cited by this paper
• Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.

  2006cited by this paper
• Bortezomib: proteasome inhibition as an effective anticancer therapy.

  2006cited by this paper
• The therapeutic potential of NS3 protease inhibitors in HCV infection

  2005cited by this paper
• Recent advances in the medicinal chemistry of alpha-aminoboronic acids, amine-carboxyboranes and their derivatives.

  2004cited by this paper
• Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

  2004cited by this paper
• Progress and development of small molecule HCV antivirals.

  2004cited by this paper
• Hepatitis C treatment update.

  2004cited by this paper
• Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.

  2003cited by this paper
• Clinical consequences of hepatitis C virus infection

  2003cited by this paper
• Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.

  2003cited by this paper
• Boronic acid compounds as potential pharmaceutical agents

  2003cited by this paper
• Side effects of therapy of hepatitis C and their management

  2002cited by this paper
• Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.

  2002cited by this paper
• P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.

  2002cited by this paper
• Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.

  2002cited by this paper
• Synthesis of boronic acid analogues of alpha-amino acids by introducing side chains as electrophiles.

  2001cited by this paper
• Total Synthesis of Motuporin (Nodularin-V)

  1999cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form

  1998cited by this paper
• The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

  1996cited by this paper
• Preparation of 2-oxygen derivatives of 1,2-oxaborolane from 2-allyloxy-1,2-oxaborolane

  1990cited by this paper
• 99% Chirally Selective Syntheses via Pinanediol Boronic Esters: Insect Pheromones, Diols, and an Amino Alcohol.

  1986cited by this paper
• (Chloromethyl)lithium: efficient generation and capture by boronic esters and a simple preparation of diisopropyl (chloromethyl)boronate

  1985cited by this paper
• Boronic ester homologation with 99% chiral selectivity and its use in syntheses of the insect pheromones (3S,4S)-4-methyl-3-heptanol and exo-brevicomin

  1983cited by this paper
• .alpha.-Chloro boronic esters from homologation of boronic esters

  1980cited by this paper

• Benzoxaborole and Beyond: The Emergence of Cyclic Hemiboronic Acids as a Versatile Chemotype in Medicine, Catalysis, and Materials.

  2026cites this paper
• Facile synthesis and spectral analysis of the bioactive spiroborate compounds as a novel therapeutic agent for computational insights, biological evaluation, and applications

  2025cites this paper
• B–N Hyperconjugation Enables Site‐Selective C–H Azidation of Alkyl and Benzyl N ‐Methyliminodiacetyl ( MIDA ) Boronates: Synthesis of α‐Azido Boronates †

  2025cites this paper
• A diastereoselective preparation of cyclic α-aminoboronates.

  2025cites this paper
• Trends on Potential Boron-containing Drugs by Advancements in Ligand-protein Crystals Complexes.

  2025cites this paper
• Exploring theophylline-1,2,4-triazole tethered N-phenylacetamide derivatives as antimicrobial agents: unraveling mechanisms via structure-activity relationship, in vitro validation, and in silico insights

  2024cites this paper
• Synthesis of Highly Substituted Oxaboroles from Oxaboranes via a Selective Petasis Borono-Mannich Reaction.

  2024cites this paper
• Molecular Docking Studies of Boron‐Containing Compounds as Dual Inhibitors of SARS‐Cov‐2 Spike Receptor Binding Domain/ACE2 Complex and Main Protease and ADMET Investigations

  2023cites this paper
• Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases

  2022cites this paper
• The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry

  2022cites this paper
• The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors

  2021cites this paper
• α-Aminoboronates: recent advances in their preparation and synthetic applications.

  2021cites this paper
• The Matteson Reaction

  2021cites this paper
• Aliphatic Oxaboroles Enabling Remarkable Recognition of Diols

  2020cites this paper
• Simple route to new oxadiazaboroles and oxadiazoles via amidoximes

  2020cites this paper
• Concise synthesis of α-amino cyclic boronates via multicomponent coupling of salicylaldehydes, amines, and B2(OH)4

  2020cites this paper
• Design and discovery of boronic acid drugs.

  2020cites this paper
• Crystal structure, 1H and 13C NMR spectral studies of 1,2,4,5-oxadiazaborole derivatives

  2019cites this paper
• A comparison of machine learning algorithms for the prediction of Hepatitis C NS3 protease cleavage sites

  2019cites this paper
• Cu-catalyzed enantioselective synthesis of tertiary benzylic copper complexes and their in situ addition to carbonyl compounds

  2018cites this paper
• Synthesis of biologically active boron-containing compounds.

  2018cites this paper
• QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).

  2017cites this paper
• Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection

  2017cites this paper
• Synthesis, characterization, antimicrobial activity, and QSAR studies of some new 6‐substituted phenyl 3‐(4‐chlorophenyl)‐3a,4,8,8a‐tetrahydro‐[1,3,2]dioxaborepino [5,6‐d]isoxazoles

  2017cites this paper
• Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.

  2016cites this paper
• Synthesis of α-aminoboronic acids.

  2016cites this paper
• Recent developments in the chemistry and biological applications of benzoxaboroles.

  2015cites this paper
• Design of Serine Protease Inhibitors

  2015cites this paper
• Classification models of HCV NS3 protease inhibitors based on support vector machine (SVM).

  2015cites this paper
• Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.

  2015cites this paper
• The Future of Boron in Medicinal Chemistry: Therapeutic and Diagnostic Applications

  2015cites this paper
• Allosteric modulation of protein oligomerization: an emerging approach to drug design

  2014cites this paper
• HCV-targeted antivirals: current status and future challenges.

  2014cites this paper
• Boronic acid-based enzyme inhibitors: a review of recent progress.

  2014cites this paper
• The unique chemistry of benzoxaboroles: current and emerging applications in biotechnology and therapeutic treatments.

  2014cites this paper
• A Divalent Protecting Group for Benzoxaboroles.

  2013cites this paper
• Role of Proteases in the Management of Hepatitis C Virus

  2013cites this paper
• Boron chemicals in diagnosis and therapeutics.

  2013cites this paper
• Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole

  2013cites this paper
• Inhibition of Toll-Like Receptor-Mediated Inflammation in vitro and in vivo by a Novel Benzoxaborole

  2012cites this paper
• Boron containing compounds as protease inhibitors.

  2012cites this paper
• Examination of the reactivity of benzoxaboroles and related compounds with a cis-diol.

  2012cites this paper
• Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.

  2011cites this paper
• Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors.

  2011cites this paper
• Cyclic boronic acid ester derivatives and therapeutic use thereof

  2011cites this paper
• Dérivés cycliques d'esters d'acide boronique et leurs utilisations thérapeutiques

  2011cites this paper
• TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

  2011cites this paper
• Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.

  2010cites this paper
• Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.

  2010cites this paper
• Medicinal Chemistry Research Synthesis, Characterization, Antimicrobial Activity, and Qsar Studies on Substituted Oxadiazaboroles

  year unknowncites this paper